# Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

> **NCT00276809** · PHASE2 · COMPLETED · sponsor: **German CLL Study Group** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **BIOLOGICAL:** filgrastim
- **DRUG:** carmustine
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** dexamethasone
- **DRUG:** etoposide
- **DRUG:** fludarabine phosphate
- **DRUG:** melphalan
- **PROCEDURE:** autologous bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00276809
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276809, "Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00276809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*